- The report introduces a quantitative timing model based on volume signals, referred to as the "Volume Timing Signal" model. The model evaluates market sentiment by analyzing the volume of major indices. As of March 6, 2026, the volume timing signals for all indices, including the Shanghai Composite Index, Shanghai 50, CSI 300, CSI 500, CSI 1000, ChiNext Index, and Beijing 50, indicate a cautious outlook[23][24] - The "HS300 Rising Stock Proportion Sentiment Indicator" is introduced to assess market sentiment by calculating the proportion of stocks in the CSI 300 index with positive returns over a specific period (N days). The formula is: $ \text{HS300 N-day Rising Stock Proportion} = \frac{\text{Number of CSI 300 stocks with positive returns over N days}}{\text{Total number of CSI 300 stocks}} $ This indicator is effective in capturing upward opportunities but has limitations in predicting market downturns. As of March 6, 2026, the indicator showed a slight increase, with the proportion of rising stocks exceeding 60%, indicating high market sentiment[24][25] - The "HS300 Rising Stock Proportion Timing Tracking" applies two different smoothing windows (N1=50 and N2=35) to the above sentiment indicator. When the short-term smoothed line (fast line) exceeds the long-term smoothed line (slow line), it signals a bullish market sentiment. As of March 6, 2026, both the fast and slow lines were rising, with the fast line above the slow line, suggesting a continued bullish outlook[26][28] - The "Moving Average Sentiment Indicator" is based on the eight-moving-average system, which uses the closing prices of the CSI 300 index and calculates moving averages with parameters 8, 13, 21, 34, 55, 89, 144, and 233. The indicator assigns values of -1, 0, or 1 based on the position of the current price relative to the moving averages. When the current price exceeds more than five of the moving averages, it signals a bullish sentiment. As of March 6, 2026, the CSI 300 index was in a non-prosperous sentiment zone[32][36] - The report also analyzes cross-sectional volatility and time-series volatility as indicators of short-term alpha opportunities. Cross-sectional volatility for CSI 300, CSI 500, and CSI 1000 index components increased week-over-week, indicating an improved short-term alpha environment. Over the past quarter, cross-sectional volatility for CSI 300 and CSI 1000 was in the upper-middle percentile of the past six months, while CSI 500 was in the middle percentile. Time-series volatility for the same indices also increased week-over-week, with CSI 1000 in the upper-middle percentile of the past six months, indicating a favorable alpha environment[37][38][41]

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2026-013 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购期间，应当在每个月的前 3 个交易日 内公告截至上月末的回购进展情况，现将公司回购股份的进展情况公告如下： 2026 年 2 月，公司未通过上海证券交易所交易系统以集中竞价交易方式回购 公司股份。 截至 2026 年 2 月 28 日，公司通过上海证券交易所交易系统以集中竞价交易 方式累计回购公司股份 93.88 万股，占公司总股本的 0.44%，回购最高价格 104.77 元/股，回购最低价格 98.14 元/股，使用资金总额为人民币 9,506.63 万元（不含印 花税、交易佣金等交易费用）。 奕瑞电子科技集团股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 ...

Core Insights - The report anticipates a fluctuating upward trend in the index, with a primary focus on style rebalancing [4][5] - The A-share market has shown signs of recovery after initial volatility, with significant performance differences among major indices [5][6] Domestic Policy and Market Liquidity - The People's Bank of China conducted a 600 billion MLF operation and net injected 300 billion, marking the 12th consecutive month of increased liquidity to ensure reasonable liquidity before and after the Spring Festival [2] - The strengthening of the RMB has stabilized expectations for cross-border capital flows [2] Sector Performance - In the technology sector, midstream high-end manufacturing has led the gains, particularly in defense, machinery, and power equipment, driven by geopolitical tensions and domestic equipment renewal cycles [2] - In the cyclical sector, building materials, steel, and coal have outperformed, with glass fiber leading due to supply-side optimization and demand from AI and new energy [3] - Conversely, the non-ferrous metals sector has seen a pullback due to fluctuating expectations around U.S. Federal Reserve interest rate cuts and geopolitical disturbances [3] Market Trends and Historical Context - Historical data from 2010 to 2025 indicates a high probability of the Shanghai Composite Index rising in the month following the Spring Festival, particularly after a month of adjustment or fluctuation [6] - The report suggests that the market is likely to follow a "diffusion" model of industry rotation rather than a dramatic style switch, with a focus on moderate rebalancing [6] Investment Strategy - The report recommends focusing on "supply constraints + visible profits" as dual main lines, particularly in midstream high-end manufacturing [6] - The core trading logic around the AI chain continues to revolve around profit visibility and supply shortages, with a cautious approach to market liquidity [6] - Opportunities for Chinese manufacturing to expand overseas are highlighted, particularly in sectors like power equipment and engineering machinery [6] Recommended Stocks - The March stock selection includes a mix of sectors such as central enterprise dividend ETFs, hospitality, electronics, military, machinery, beverages, and communications [10]

Market Overview - A-shares concluded February with the Shanghai Composite Index achieving three consecutive monthly gains, and daily trading volumes exceeding 1 trillion yuan have become the norm [1][20] - On February 27, the three major indices showed mixed results, with over 3,200 stocks rising and a total trading volume of 2.51 trillion yuan, slightly down by 504 billion yuan from the previous day [1][20] Sector Performance - The small metals sector surged, with rare earth prices continuing to rise, leading to a wave of limit-up stocks including Hunan Gold [21][23] - The chemical sector also performed well, with the chemical ETF achieving four consecutive daily gains, reaching its highest point since January 2022 [21][23] AI and Technology Impact - China's AI token usage surpassed that of the US for the first time, indicating a potential benefit for domestic computing power [21][29] - The cloud computing sector is entering a price increase cycle, with the big data ETF seeing a significant price increase [21][29] Electricity Sector - The electricity sector experienced a strong rally, with the electricity ETF rising by 2.64%, reaching a new high since its listing [2][26] - The demand for electricity is expected to increase due to the growth of AI, making it a defensive investment in the current market environment [2][29] Medical Sector - The largest medical ETF in the market saw a price increase of 1.14%, recovering its annual line, with significant net subscriptions in the previous days [2][29] - The medical sector is expected to benefit from the growth of the CXO model, with strong performance from companies like WuXi AppTec [12][29] Investment Recommendations - Focus on cyclical commodities such as chemicals, non-ferrous metals, and agricultural products, as well as sectors related to technology and national strength, such as military and new energy [22] - The medical sector is recommended for investment, particularly in areas like AI healthcare and medical devices, which are expected to see significant growth [15][16]

Group 1 - The A-share medical sector showed positive performance on February 27, with the largest medical ETF (512170) rising by 1.14% and successfully recovering the annual line, with a transaction volume of 384 million CNY [1][9] - The ETF experienced continuous premium trading, indicating a positive buying sentiment, with over 190 million CNY net subscriptions in the previous three days [1][9] - The leading stock, Huatai Medical, surged by 8.24%, with its performance report indicating over 20% year-on-year growth in revenue and net profit for 2025 [1][11] Group 2 - The Hong Kong medical sector rebounded after several days of decline, with the Hong Kong medical ETF (159137) recovering from a historical low, ending a six-day losing streak [3][11] - CXO companies, particularly those under WuXi AppTec, showed strong performance, with shares rising by 8.23% for WuXi AppTec, 5% for WuXi Biologics, and 3.21% for WuXi AppTec [3][11] - Citic Securities remains optimistic about the growth potential and space for the CXO sector due to increasing overseas orders and a gradual recovery in domestic demand [4][12] Group 3 - In the medical device industry, Citic Securities believes that policy impacts will eventually clear, and companies will gradually recover after strategic adjustments, suggesting an allocation increase in 2026 [6][14] - Investment opportunities are expected to arise from performance recovery, international expansion, brain-computer interfaces, and AI medical applications [6][14] - The medical ETF fund size reached 27.7 billion CNY, making it the largest in the medical sector, covering various themes including brain-computer interfaces and innovative medical devices [7][14]

Core Viewpoint - The healthcare sector is experiencing positive momentum, with the largest healthcare ETF (512170) showing strong performance and attracting significant net inflows of capital [1][8]. Group 1: ETF Performance - On February 27, the healthcare ETF (512170) initially rose over 1% and maintained a positive trend, outperforming the broader market [1][8]. - The ETF saw a net subscription of over 115 million yuan in the previous day, indicating strong investor interest [1][8]. - As of February 24, the healthcare ETF has a total fund size of 27.7 billion yuan, making it the largest in the healthcare sector [5][12]. Group 2: Company Earnings Reports - Huatai Medical reported an expected revenue of 2.584 billion yuan for 2025, representing a year-on-year increase of 25%, with a net profit of 821 million yuan, up 22% [3][10]. - Other companies within the ETF, such as United Imaging and Yirui Technology, also reported significant net profit growth rates exceeding 40% [3][10]. - In contrast, Hotgen Biotech is projected to incur a loss of over 200 million yuan [3][10]. Group 3: Stock Movements - Huatai Medical's stock surged over 11% in early trading, currently leading the sector with a nearly 7% increase [4][10]. - Other stocks like Yingke Medical and Meihua Medical also saw gains, while Jinsong Biological experienced a decline of over 2% [4][10].

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 奕瑞电子科技集团股份有限公司（以下简称"公司"）于2026年1月23日召开第三届董事会第二十四次会 议审议通过了《关于〈公司2026年员工持股计划（草案）〉及其摘要的议案》《关于〈公司2026年员工 持股计划管理办法〉的议案》等相关议案，具体内容详见公司于2026年1月24日在上海证券交易所网站 （www.sse.com.cn）披露的相关公告。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688301 证券简称：奕瑞科技 公告编号：2026-012 转债代码：118025 转债简称：奕瑞转债 奕瑞电子科技集团股份有限公司 关于2026年员工持股计划完成股票购买的公告 公司将按照相关法律、行政法规的规定及时履行信息披露义务。敬请广大投资者关注相关公告并注意投 资风险。 特此公告。 奕瑞电子科技集团股份有限公司董事会 2026年2月27日 根据《关于上市公司实施员工持股计划试点的指导意见》及《上海证券交易所科创板上市公司自律监管 指引第1号一一规范运作》等相关法规要 ...

格隆汇2月26日丨奕瑞科技(688301.SH)公布，截至本公告披露日，公司2026年员工持股计划已完成标的 股票的购买，通过《2026年员工持股计划（草案）》规定的方式累计买入公司股票1,018,847股，占公司 总股本的0.48%，成交金额为9,806.93万元（不含佣金、过户费等交易费用）。上述股票将按照公司 2026年员工持股计划的相关规定予以锁定，自本公告披露之日锁定12个月。锁定期满后，在满足相关考 核条件的前提下，一次性解锁并分配权益至持有人。 ...

格隆汇2月26日丨奕瑞科技(688301.SH)公布，截至本公告披露日，公司2026年员工持股计划已完成标的 股票的购买，通过《2026年员工持股计划（草案）》规定的方式累计买入公司股票1,018,847股，占公司 总股本的0.48%，成交金额为9,806.93万元（不含佣金、过户费等交易费用）。上述股票将按照公司 2026年员工持股计划的相关规定予以锁定，自本公告披露之日锁定12个月。锁定期满后，在满足相关考 核条件的前提下，一次性解锁并分配权益至持有人。 ...

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2026-012 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 关于 2026 年员工持股计划完成股票购买的公告 特此公告。 奕瑞电子科技集团股份有限公司董事会 2026年2月27日 奕瑞电子科技集团股份有限公司（以下简称"公司"）于2026年1月23日召开第 三届董事会第二十四次会议审议通过了《关于<公司2026年员工持股计划（草案） >及其摘要的议案》《关于<公司2026年员工持股计划管理办法>的议案》等相关 议 案 ， 具 体 内 容 详 见 公 司 于 2026 年 1 月 24 日 在 上 海 证 券 交 易 所 网 站 （ www.sse.com.cn）披露的相关公告。 根据《关于上市公司实施员工持股计划试点的指导意见》及《上海证券交易所 科创板上市公司自律监管指引第1号——规范运作》等相关法规要求，现将公司 2026年员工持股计划实施进展情况公告如下： 截至本公告披露日，公司2026年员工持股计划已完成标的股票的购买，通过 《2026 年员工持 ...